Compare RYTM & BIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RYTM | BIO |
|---|---|---|
| Founded | 2008 | 1952 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Laboratory Analytical Instruments |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.4B | 7.2B |
| IPO Year | 2017 | N/A |
| Metric | RYTM | BIO |
|---|---|---|
| Price | $93.06 | $271.18 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 14 | 4 |
| Target Price | $129.43 | ★ $358.50 |
| AVG Volume (30 Days) | ★ 739.0K | 304.0K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 28.34 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $58.38 | $2.51 |
| Revenue Next Year | $83.95 | $3.17 |
| P/E Ratio | ★ N/A | $9.72 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $45.91 | $211.43 |
| 52 Week High | $122.20 | $343.12 |
| Indicator | RYTM | BIO |
|---|---|---|
| Relative Strength Index (RSI) | 40.55 | 40.62 |
| Support Level | $83.98 | $266.71 |
| Resistance Level | $96.92 | $290.01 |
| Average True Range (ATR) | 4.81 | 7.40 |
| MACD | -0.45 | 1.11 |
| Stochastic Oscillator | 31.11 | 33.68 |
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.